4 Healthcare Stock Stories for Thursday Investment Wellness

HealthSouth Corp. (NYSE:HLS): Closing price $26.42

HealthSouth has purchased land, and expects to to build a new approximately 54,000-square foot inpatient rehabilitation hospital in Modesto. Connected with these plans, HealthSouth acquired 5.5 acres of land located at the northeast corner of Coffee Road and Mable Avenue in that city. The development should represent a $28 million investment in the community, and once fully operational, about 100 full-time jobs.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

HLS

Array BioPharma (NASDAQ:ARRY): Closing price $5.09

On Thursday, Array said that results from two ongoing ARRY-520 clinical trials in multiple myeloma were presented at the 2013 International Myeloma Workshop in Kyoto. ARRY-520 is a potent, selective KSP inhibitor with a mechanism of action which is distinct from other drugs used to treat MM that continues to advance in clinical trials.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ARRY

Valeant Pharmaceuticals International (NYSE:VRX): Closing price $72.64

J. Michael Pearson reacted for Valeant Thursday to Mylan’s generic approval for Zovirax ointment: ”Yesterday, Mylan announced they had received approval of a generic Zovirax ointment. While the timing of a generic approval was always uncertain, this was not unforeseen and we were prepared for its eventuality. In response to the new generic approval, we will be launching an authorized generic of Zovirax ointment today.  Valeant’s business model is based on diversification which allows us to better balance sudden events such as this.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

VRX

Pfizer (NYSE:PFE): Current price $29.15

Tetragenetics has reached a collaboration agreement with an option with Pfizer for an exclusive license for SionX. The SionX tech allows high density expression of recombinant human ion channels on the cell membranes of Tetrahymena thermophila. Immunogen preparations of the ion channel are created to enhance antibody production against the extracellular portions of the ion channel target.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

PFE

Investing Insights: Is Johnson and Johnson a Safe Investment?